Approval · Notice of Compliance 11911 · 2010
MINT-RISPERIDON: Notice of Compliance 11911
Issued December 8, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11911
- Date
- December 8, 2010
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antipsychotic agent
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-RISPERIDON | 02359790 | Marketed |
| MINT-RISPERIDON | 02359804 | Marketed |
| MINT-RISPERIDON | 02359812 | Marketed |
| MINT-RISPERIDON | 02359820 | Marketed |
| MINT-RISPERIDON | 02359839 | Marketed |
| MINT-RISPERIDON | 02359847 | Marketed |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB